Biology might ultimately provide a solution, however. Researchers have identified bacteria that evolved the ability to digest ...

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.

Among the systems that fit the criteria of traveling networks, the researchers identified very different candidates: the actin cytoskeleton—a network of monomeric protein units that disassemble ...

But real lightning would have struck infrequently—and mostly in open ocean, where organic compounds would have quickly ...

which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revolutionized drug discovery, effective ...

A research team, led by Professor Dong Woog Lee from the Department of Chemistry at UNIST, in collaboration with Professor ...

Addressing the harmful chemical processes that accompany blunt force trauma to the brain can reduce the risk of long-term disability.

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...